Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Endothelin receptor antagonist

Macitentan

OPSUMIT

Dosage form
Tablet
Available strengths
10 mg film-coated tablet; 2.5 mg dispersible tablet
Drug class
Endothelin receptor antagonist
Common brand
OPSUMIT

Clinical overview. Macitentan is an endothelin receptor antagonist (brand name OPSUMIT) taken once daily by mouth for the long-term treatment of pulmonary arterial hypertension in adults and children 2 years and older. It requires regular blood tests to monitor hemoglobin and liver function, and is strictly contraindicated during pregnancy and breastfeeding due to fetal risk. Common effects include headache, anemia, and respiratory infections, while liver injury and interactions with strong CYP3A4 inhibitors or inducers are important safety considerations.

Indication

Common therapeutic uses

  • Macitentan is used for the long-term treatment of pulmonary arterial hypertension (WHO Group I) to reduce disease-related complications in adults with WHO Functional Class II or III disease that is idiopathic, heritable, or associated with connective tissue disease or congenital heart disease.
  • Macitentan is used for the same indication in pediatric patients aged 2 to less than 18 years.
  • Macitentan is effective when used alone or in combination with a phosphodiesterase-5 inhibitor such as sildenafil.

Pregnancy

Risk assessment and monitoring considerations

Contraindicated in pregnancy. Confirm pregnancy status and discuss alternative therapy with the prescriber before dispensing.

  • Macitentan is contraindicated in women who are or may become pregnant, since pulmonary arterial hypertension itself carries a high mortality risk in pregnancy and macitentan was teratogenic in animal studies.
  • In animal studies, macitentan caused cardiovascular and mandibular arch fusion abnormalities in rabbits and rats at all doses tested.
  • Treatment should only be started in women of childbearing potential after a negative pregnancy test, with reliable contraception in place, and monthly pregnancy testing is recommended during treatment.
  • Women should not become pregnant for at least 1 month after stopping macitentan.

Breastfeeding

Infant exposure considerations

  • Macitentan is contraindicated in women who are breastfeeding.
  • It is not known whether macitentan passes into human milk, though macitentan and its metabolites were found in the milk of lactating rats.

Geriatrics

Dosing and tolerability considerations

  • Dose adjustment is not required in patients 65 years of age and older.
  • There is limited clinical experience in patients over 75 years of age, so macitentan should be used with caution in this group.

Pediatrics

Use in children and adolescents

  • Macitentan is authorized for pediatric patients aged 2 to less than 18 years, using dispersible tablets dosed according to body weight.
  • Safety and efficacy have not been established in children under 2 years of age, so use is not authorized in this age group.
  • The safety profile in pediatric patients was generally consistent with adults, though upper respiratory tract infection, rhinitis, and gastroenteritis were reported more often than in the comparator group.

Dosage & Administration

Practical dosing and administration

  • The recommended adult dose is one 10 mg film-coated tablet taken by mouth once daily.
  • In pediatric patients weighing 10 kg to less than 20 kg, the dose is 5 mg daily, given as two 2.5 mg dispersible tablets.
  • In pediatric patients weighing 20 kg to less than 40 kg, the dose is 7.5 mg daily, given as three 2.5 mg dispersible tablets.
  • In pediatric patients weighing 40 kg or more, the dose is 10 mg daily, given as four 2.5 mg dispersible tablets.
  • Dispersible tablets must be mixed into a small volume of room-temperature water, juice, or milk to form a suspension and given immediately, then followed with a little more liquid to ensure the full dose is taken.
  • Film-coated tablets should be swallowed whole and can be taken with or without food.
  • No dose adjustment is required for mild hepatic impairment, but macitentan is not recommended in patients with moderate or severe hepatic impairment due to lack of clinical experience.
  • Macitentan is not recommended in patients undergoing dialysis; monitor blood pressure and hemoglobin in patients with moderate or severe renal impairment given an increased risk of hypotension and anemia.
  • If a dose is missed, take it as soon as remembered, but skip it and resume the normal schedule the next day if it is nearly time for the next dose; never take two doses on the same day to make up for a missed one.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • There is no clinical experience with macitentan overdose.
  • In a study using single doses up to 600 mg, healthy subjects experienced headache, nausea, and vomiting.
  • Overdose should be managed with standard supportive measures as needed.
  • Because macitentan is highly bound to blood proteins, dialysis is not expected to be effective at removing it.

Common side effects

Frequently reported tolerability concerns

  • Nasal and throat inflammation (nasopharyngitis) may occur.
  • Headache may occur.
  • Reduced red blood cell count (anemia) may occur.
  • Bronchitis may occur.
  • Urinary tract infection may occur.
  • Increased or irregular uterine (menstrual) bleeding may occur.
  • Sore throat (pharyngitis) may occur.
  • Flu-like illness (influenza) may occur.
  • Fluid retention or swelling (edema) may occur.
  • Low blood pressure (hypotension) may occur.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Decreased hemoglobin and anemia requiring transfusion have been reported; treatment is not recommended in patients with severe anemia.
  • Elevated liver enzymes and liver injury, including cases with alternative causes such as autoimmune hepatitis, have been reported; treatment should be discontinued for significant liver enzyme elevations or symptoms of liver injury such as jaundice.
  • Pulmonary edema can occur in patients with underlying pulmonary veno-occlusive disease.
  • Male infertility may occur, based on decreased sperm counts observed with endothelin receptor antagonists; it is not known whether this effect is reversible.
  • Hypersensitivity reactions, including angioedema, itching, and rash, have been reported.
  • Pathologic changes in testicular tissue have been observed in animal studies at high exposures.
  • Seek prompt medical attention for yellowing of the skin or eyes, unusual fatigue, swelling, fainting, or heavy vaginal bleeding.

Use with caution

Situations requiring closer assessment

  • Use with caution, with hemoglobin measured before starting treatment, after one month, and periodically thereafter, given the known risk of anemia.
  • Use with caution, with liver enzyme tests obtained before starting treatment and monthly during the first year, given the risk of liver injury.
  • Do not start treatment in patients with liver aminotransferases already more than 3 times the upper limit of normal.
  • Use with caution in patients with moderate or severe renal impairment, monitoring blood pressure and hemoglobin due to an increased risk of hypotension and anemia.
  • Use with caution in men of reproductive potential, and counsel them about the possible effect on fertility.
  • Use with caution in patients over 75 years of age, given limited clinical experience in this group.
  • Consider pulmonary veno-occlusive disease if signs of pulmonary edema develop after starting treatment.
  • Re-initiation of macitentan after stopping for liver enzyme elevations may be considered once levels return to normal in patients without symptoms of liver injury.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with known hypersensitivity to macitentan or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container.
  • Contraindicated in women who are or may become pregnant.
  • Contraindicated in women who are breastfeeding.

Drug interactions

Clinically relevant combinations

  • Macitentan is metabolized mainly by CYP3A4, with minor contributions from CYP2C8, CYP2C9, and CYP2C19.
  • Strong CYP3A4 inhibitors, such as ketoconazole, itraconazole, voriconazole, clarithromycin, and ritonavir, increase macitentan exposure, so caution is advised when these are combined with macitentan.
  • Moderate dual inhibitors of CYP3A4 and CYP2C9, such as fluconazole and amiodarone, or the combination of a moderate CYP3A4 inhibitor (such as diltiazem, erythromycin, or cyclosporine) with a CYP2C9 inhibitor, can significantly increase macitentan exposure and require caution.
  • Strong CYP3A4 inducers, such as rifampicin, substantially reduce macitentan exposure and should be avoided in combination, as this may reduce efficacy.
  • Macitentan did not have a clinically relevant effect on the pharmacokinetics of sildenafil, and the combination has been shown to be effective and safe in pulmonary arterial hypertension.
  • Macitentan did not affect the pharmacokinetics or effectiveness of hormonal contraceptives, so no dose adjustment is warranted.
  • Macitentan did not have a clinically relevant effect on warfarin pharmacokinetics or its anticoagulant effect on INR.
  • Macitentan did not affect the pharmacokinetics of rosuvastatin, a breast cancer resistance protein substrate, or of riociguat.

Food interactions

Meal-related administration

  • Macitentan exposure is unchanged by food, so it can be taken with or without meals.

Time of administration

Practical scheduling

  • Take macitentan once daily at about the same time each day, with or without food.

Storage

Product handling

  • Store at room temperature between 15°C and 30°C in the original package.

Patient take-away

Key counselling points for a quick closing summary

  • Macitentan (OPSUMIT) is a once-daily tablet used long-term to treat pulmonary arterial hypertension and reduce disease-related complications.
  • Blood tests to check hemoglobin and liver function are needed before starting treatment and periodically during treatment.
  • Macitentan must not be used during pregnancy or breastfeeding, and women of childbearing potential need a negative pregnancy test and reliable contraception before and during treatment.
  • Seek prompt medical attention for yellowing of the skin or eyes, unusual tiredness, fainting, or heavy vaginal bleeding while on this medication.

References

Source material and product information

  1. Health Canada Product Monograph — Macitentan

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.